Everolimus in Patients With Advanced Follicular-Derived Thyroid Cancer: Results of a Phase II Clinical Trial

Tatiana C. Schneider; Djoeke de Wit; Thera P. Links; Nielka P. van Erp; Jakobus J. M. van der Hoeven; Hans Gelderblom; Inge C. F. M. Roozen; Manon Bos; Wim E. Corver; Tom van Wezel; Jan W. A. Smit; Hans Morreau; Henk-Jan Guchelaar; Ellen Kapiteijn

首页> 外文期刊>The journal of clinical endocrinology and metabolism >Everolimus in Patients With Advanced Follicular-Derived Thyroid Cancer: Results of a Phase II Clinical Trial

【24h】

Everolimus in Patients With Advanced Follicular-Derived Thyroid Cancer: Results of a Phase II Clinical Trial

机译：晚期滤泡性甲状腺癌患者的依维莫司：II期临床试验的结果

获取原文

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

AbstractBackground:Mammalian target of rapamycin (mTOR) upregulation has been reported to be involved in the pathogenesis of thyroid tumors, and treatment with the mTOR inhibitor everolimus has shown promising results in endocrine tumors. We conducted a prospective phase II clinical trial to determine the efficacy and safety of everolimus in patients with advanced follicular-derived thyroid cancer.

机译：摘要背景：雷帕霉素（mTOR）上调的哺乳动物靶点已被报道参与甲状腺肿瘤的发病机理，而mTOR抑制剂依维莫司的治疗在内分泌肿瘤中显示出令人鼓舞的结果。我们进行了一项前瞻性II期临床试验，以确定依维莫司在晚期滤泡性甲状腺癌患者中的疗效和安全性。

著录项

来源
《The journal of clinical endocrinology and metabolism》 |2017年第2期|共10页
作者
Tatiana C. Schneider; Djoeke de Wit; Thera P. Links; Nielka P. van Erp; Jakobus J. M. van der Hoeven; Hans Gelderblom; Inge C. F. M. Roozen; Manon Bos; Wim E. Corver; Tom van Wezel; Jan W. A. Smit; Hans Morreau; Henk-Jan Guchelaar; Ellen Kapiteijn;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类代谢病;
关键词

相似文献

外文文献
中文文献
专利

1. Erratum for “Everolimus in Patients With Advanced Follicular-Derived Thyroid Cancer: Results of a Phase II Clinical Trial” [J] . The journal of clinical endocrinology and metabolism . 2017,第6期

机译：勘误表“晚期滤泡源性甲状腺癌患者的依维莫司：II期临床试验结果”
2. Erratum for “Everolimus in Patients With Advanced Follicular-Derived Thyroid Cancer: Results of a Phase II Clinical Trial” [J] . The journal of clinical endocrinology and metabolism . 2017,第6期

机译：勘误表“晚期滤泡源性甲状腺癌患者的依维莫司：II期临床试验结果”
3. A multicenter, phase II trial of everolimus in locally advanced or metastatic thyroid cancer of all histologic subtypes [J] . LimS.M., ChangH., YoonM.J., Annals of oncology: official journal of the European Society for Medical Oncology . 2013,第12期

机译：依维莫司在所有组织学亚型的局部晚期或转移性甲状腺癌的多中心II期试验中
4. Phase I/II clinical trials on the effect of weekly paclitaxel (wPTX) and wPTX containing combination regimens for advanced and metastatic gastric cancer -ECRIN group studies [C] . Sakamoto J, Kodera Y, Kobayashi M, International Gastric Cancer Congress . 2009

机译：I / II期临床试验关于每周紫杉醇（WPTX）和WPTX含有晚期和转移性胃癌组合方案的临床试验 - 分泌组研究
5. Clinical predictive value of pre-clinical cancer models: A study of the predictive value of the in vitro cell line, human xenograft and murine allograft pre-clinical cancer models for phase II clinical trials of cytotoxic cancer drugs [D] . Voskoglou-Nomikos, Theodora 2001

机译：临床前癌症模型的临床预测价值：体外细胞系，人异种移植和小鼠同种异体移植临床前癌症模型对细胞毒性癌症药物II期临床试验的预测价值研究
6. Beneficial Effects of the mTOR Inhibitor Everolimus in Patients with Advanced Medullary Thyroid Carcinoma: Subgroup Results of a Phase II Trial [O] . T. C. Schneider, D. de Wit, T. P. Links, 2015

机译：mTOR抑制剂依维莫司对晚期髓样甲状腺癌患者的有益作用：II期试验的亚组结果
7. Erratum for “Everolimus in Patients With Advanced Follicular-Derived Thyroid Cancer: Results of a Phase II Clinical Trial” [O] . 2017

机译：“先进卵泡型甲状腺癌患者血尿症患者的错误：II期临床试验的结果”

Everolimus in Patients With Advanced Follicular-Derived Thyroid Cancer: Results of a Phase II Clinical Trial

摘要

著录项

相似文献

相关主题

期刊订阅